Digest Network Come funziona
Network
/
Società
Su
Non verificato

Sumitomo Pharma America, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

10 comunicati stampa

Guarda tutti i comunicati
04/11/2026
Eventi
Industria
Biotecnologia
Management
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
02/11/2026
Holly Robinson Peete and Rodney Peete Hit the Road with GEMTESA® for the Next Chapter of the Time To Go™ Campaign
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
26/10/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
12/08/2026
Industria
Scienza
Biotecnologia
Medicina - Varie
Biologia
Salute
Farmaceutica
Ottica
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
06/08/2026
Eventi
Industria
Sanità
Salute
Biotecnologia
Farmaceutica
Oncologia
Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
30/07/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
15/06/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
10/06/2026
Industria
Oncologia
Salute
Management
Medicina - Varie
Farmaceutica
Biotecnologia
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0
18/05/2026
Scienza
Terza età
Medicina - Varie
Biotecnologia
Salute
Vetrine/Shopping
Farmaceutica
Oncologia
Eventi
Industria
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
Fonte
Sumitomo Pharma America, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0